Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Antidote To Synthetic Cannabis ‘Spice’ Intoxication Could Be Found In Slimming Drug

By QUEEN MARY UNIVERSITY OF LONDON | October 5, 2017

Early research from Queen Mary University of London has potentially found an antidote that can rapidly stop the intoxicating effects of cannabis and synthetic cannabinoids.

Synthetic cannabinoids, such as ‘Spice’ and ‘Black Mamba’, are becoming an increasing problem, especially with youths game to experiment and within the homeless and prison populations, due to their cheapness and odourless properties. Their super strength compared to cannabis is leading to an increasing number of severe adverse reactions and an increasing number of deaths.

The study, published in the British Journal of Pharmacology, looked at mice that were experiencing the effects of synthetic cannabinoid intoxication, to see the effects of treating them with a molecule known as AM251.

AM251 blocked the action of the synthetic cannabinoid on one of the brain receptors and led to a loss of the cannabinoid-related behavioural effects within a few minutes. This included a significant loss of sedation within 20 minutes, and a loss of the associated hypothermia within 40 minutes.

The researchers say that the most rapid way to develop an antidote would be to re-develop one of the slimming drugs, known as rimonabant, which also blocks the cannabinoid system on which marijuana acts.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50